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Abstract
Background: In addition to systemic inflammation, neuroinflammation in the brain, which enhances sympathetic
drive, plays a significant role in cardiovascular diseases, including hypertension. Oxidative stress in rostral
ventrolateral medulla (RVLM) that augments sympathetic outflow to blood vessels is involved in neural mechanism
of hypertension. We investigated whether neuroinflammation and oxidative stress in RVLM contribute to
hypertension following chronic systemic inflammation.
Methods: In normotensive Sprague-Dawley rats, systemic inflammation was induced by infusion of Escherichia coli
lipopolysaccharide (LPS) into the peritoneal cavity via an osmotic minipump. Systemic arterial pressure and heart
rate were measured under conscious conditions by the non-invasive tail-cuff method. The level of the inflammatory
markers in plasma or RVLM was analyzed by ELISA. Protein expression was evaluated by Western blot or
immunohistochemistry. Tissue level of superoxide anion (O2•
-) in RVLM was determined using the oxidation-sensitive
fluorescent probe dihydroethidium. Pharmacological agents were delivered either via infusion into the cisterna
magna with an osmotic minipump or microinjection bilaterally into RVLM.
Results: Intraperitoneal infusion of LPS (1.2 mg/kg/day) for 14 days promoted sustained hypertension and induced
a significant increase in plasma level of C-reactive protein, tumor necrosis factor-α (TNF-α), or interleukin-1β (IL-1β).
This LPS-induced systemic inflammation was accompanied by activation of microglia, augmentation of IL-1β, IL-6,
or TNF-α protein expression, and O2•- production in RVLM, all of which were blunted by intracisternal infusion of a
cycloxygenase-2 (COX-2) inhibitor, NS398; an inhibitor of microglial activation, minocycline; or a cytokine synthesis
inhibitor, pentoxifylline. Neuroinflammation in RVLM was also associated with a COX-2-dependent downregulation
of endothelial nitric oxide synthase and an upregulation of intercellular adhesion molecule-1. Finally, the LPS-
promoted long-term pressor response and the reduction in expression of voltage-gated potassium channel, Kv4.3
in RVLM were antagonized by minocycline, NS398, pentoxifylline, or a superoxide dismutase mimetic, tempol, either
infused into cisterna magna or microinjected bilaterally into RVLM. The same treatments, on the other hand, were
ineffective against LPS-induced systemic inflammation.
Conclusion: These results suggest that systemic inflammation activates microglia in RVLM to induce COX-2-
dependent neuroinflammation that leads to an increase in O2•
- production. The resultant oxidative stress in RVLM in
turn mediates neurogenic hypertension.
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Background
There are increasing indications that chronic inflamma-
tion plays a critical role in the pathogenesis of cardiovas-
cular diseases, including atherosclerosis, heart failure,
diabetes mellitus, and hypertension [1-4]. In addition to
the well characterized involvement of proinflammatory
cytokines, including tumor necrosis factor-α (TNF-α)
and interleukins (ILs) in endothelial cells [5], and vascu-
lar smooth muscle cells [5,6] in cardiovascular remodel-
ing during disease conditions, recent focus has shifted to
the role of brain inflammation in the pathogenesis of
cardiovascular diseases [2,4,7,8]. For example, expression
of both TNF-α and IL-1β in the paraventricular nucleus
of hypothalamus (PVN), a cardiovascular regulatory re-
gion in the forebrain, is increased in rats with ischemia-
induced heart failure [9]. Activation of the peripheral or
brain renin-angiotensin system increases the production
of pro-inflammatory cytokines within specific brain
regions involved in blood pressure control [7,8,10],
resulting in hypertension. In the spontaneously hyper-
tensive rats, the pro-inflammatory chemotactic proteins
are highly expressed in brain stem nuclei involved in
cardiovascular regulation [11,12]. Treatments that are
beneficial to heart failure [9] or hypertension [13,14] also
promote anti-inflammatory effects in the brain.
Neuroinflammation is associated with an increase in
sympathetic drive during cardiovascular disease [2,15].
An increase in sympathetic outflow to the peripheral
vasculature from the rostral ventrolateral medulla
(RVLM), where premotor neurons for the maintenance
of sympathetic vasomotor activity are located [16], con-
tributes to neural mechanism of hypertension [17].
Abundant evidence now suggests that oxidative stress
because of an imbalance of production over degradation
of the reactive oxygen species (ROS), in particular super-
oxide anion (O2•
-), in RVLM contributes to neurogenic
hypertension [18,19]. Whether neuroinflammation serves
as a molecular signal for ROS activation in RVLM, lead-
ing to neurogenic hypertension, however, is currently
unknown.
A well-studied model of peripheral inflammation in
rodents is systemic administration of Escherichia coli
lipopolysaccharide (LPS) from gram-negative bacteria to
induce innate immune response. The present study took
advantage of this model to evaluate changes in the ex-
pression of pro-inflammatory cytokines in RVLM during
the course of chronic systemic inflammation and delin-
eate the underlying mechanisms. We also deciphered
the role of ROS in RVLM on development of neurogenic
hypertension following peripheral LPS administration.
Our data show that long-term LPS-induced systemic in-
flammation activates microglia and increases the expres-
sion of proinflammatory cytokines in RVLM, leading to
oxidative stress-associated neurogenic hypertension.
Methods
Animals
Adult, male Sprague-Dawley rats (10-week-old, 200 to
250 g, n=146) were purchased from the Experimental
Animal Center of the National Applied Research La-
boratories, Taiwan. Animals were maintained under
temperature control (24±0.5°C) and 12-h light-dark cycle
(lights on between 08:00 and 20:00), and provided with
standard chow and tap water ad libitum. All experimen-
tal procedures were carried out in compliance with the
guidelines of our institutional animal care and use
committee.
Induction of low-grade systemic inflammation
Systemic inflammation was induced by continuous infu-
sion of Escherichia coli LPS into the peritoneal cavity for
14 days via an osmotic minipump. On the day of im-
plantation, animals were anesthetized with sodium
pentobarbital (50 mg/kg, i.p.) and an osmotic minipump
(Alzet 1002; Durect Co., Cupertino, CA, USA) was
placed in the peritoneal cavity. Control animals received
saline-filled osmotic minipumps, and sham-operated
animals received identical surgical procedures only. We
found in our pilot study that whereas low doses of LPS
(0.3 to 1.2 mg/kg/day) infusion induced systemic inflam-
mation and a long-term pressor response, higher dose
(5.0 or 10 mg/kg/day) resulted in fever and septic-like
hypotension. Intraperitoneal (IP) infusion of LPS at a
dose of 1.2 mg/kg/day was therefore used in the present
study to induce low-grade systemic inflammation.
General experimental protocol
Baseline systemic arterial pressure (SAP) and heart rate
(HR) were recorded for 3 days, followed by daily record-
ing after IP infusion of LPS (1.2 mg/kg/day) or saline
for 14 days. Body weight, body temperature, food, and
water intake of the animals were recorded daily for
14 days. Some animals received additional intracisternal
(IC) or IP infusion of NS398 (1.5 nmol/μL/h), minocy-
cline (9 nmol/μL/h), PTX (30 nmol/μL/h), tempol
(1 μmol/μL/h), or aCSF for 14 days; or additional IP infu-
sion of the same dose of NS398, minocycline, or tempol
for 14 days. Other groups received additional microinjec-
tion bilaterally into RVLM or intravenous injection of the
same dose of tempol on day 7 after the beginning of LPS
infusion. At various post-treatment intervals, animals were
killed to collect blood and RVLM tissues for molecular,
biochemical, and immunohistochemical experiments.
Measurement of systemic arterial pressure and heart rate
We routinely measured SAP and HR between 14:00 and
16:00 in conscious rats using the non-invasive tail-cuff
electrosphygmomanometry (MK-2000; Momuroki Kikai
Co., Japan) method according to the previously described
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procedures [20]. Tail-cuff plethysmography instead of
radiotelemetry was used in this study for measurement of
SAP to reduce potential confounding influence by the
implanted telemetry transmitter in the peritoneal cavity
on the induced systemic inflammation. We have previ-
ously validated that SAP and HR obtained by tail-cuff
plethysmography were comparable to those measured by
radiotelemetry [20].
Power spectral analysis of systemic arterial pressure
signals
The recorded SAP signals were simultaneously subject
to power spectral analysis. We were particularly inter-
ested in the low-frequency (LF, 0.25 to 0.8 Hz) compo-
nents of SAP signals. This spectral component of SAP
signals was reported to take origin from the RVLM [21],
and reflect the prevalence of baroreflex-mediated sym-
pathetic neurogenic vasomotor tone [22].
Analysis of plasma inflammatory markers
One milliliter of blood was collected from the heart and
mixed with 1 mL MinicollectW tripotassium EDTA
(Greiner bio-one, Monroe, NC, USA) for quantitative
analysis of TNF-α, IL-1β, or IL-6 by the sandwich ELISA
(Bender MedSystems, Burlingame, CA, USA) according
to the manufacturer’s instructions. Plasma C-reactive
protein (CRP) was measured by BD™ ELISA Rat CRP
kit (BD Biosciences, San Diego, CA, USA). The colori-
metric reaction product for individual pro-inflammatory
factor was measured at 450 nm using a microplate
reader (Dynex, Chantilly, VA, USA). The concentration
of TNF-α, IL-1β, IL-6, or CRP, expressed in micrograms
per milliliter (μg/mL), was determined from the regres-
sion line for the standards incubated under the same
conditions in each assay. All assays were performed in
triplicate.
Collection of tissue samples from RVLM
At various time intervals after experimental treatment,
rats were killed with an overdose of pentobarbital so-
dium (100 mg/kg, i.p.) and perfused intracardially with
warm saline. The brain was rapidly removed and imme-
diately frozen on dry ice. The medulla oblongata cover-
ing RVLM was blocked between 0.5 and 1.5 mm rostral
to the obex, as adopted from the atlas of Watson and
Paxinos [23]. Both sides of the ventrolateral medulla
covering RVLM (approximately 1.5-mm to 2.5-mm lat-
eral to the midline and medial to the spinal trigeminal
tract) were collected by micropunches with a 1-mm
inner diameter stainless-steel burr [18-20]. Medullary
tissues collected were stored at -80°C for subsequent
protein analysis.
Total protein isolation
Tissue samples from RVLM were homogenized with a
Dounce grinder with a tight pestle in ice-cold lysis buffer
(15 mM HEPES, pH 7.2, 60 mM KCl, 10 mM NaCl,
15 mM MgCl2, 250 mM Sucrose, 1 mM EGTA, 5 mM
EDTA, 1 mM PMSF, 2 mM NaF, 4 mM Na3VO4,). A
mixture of leupeptin (8 μg/mL), aprotinin (10 μg/mL),
phenylmethylsulfonyl fluoride (20 μg/mL), and trypsin
inhibitor (10 μg/mL) was included in the isolation buffer
to prevent protein degradation. The homogenate was
centrifuged at 13,500g for 10 min, and the supernatant
was collected for protein analysis. The concentration of
the total protein extracted was estimated by the method
of Bradford with a protein assay kit (Bio-Rad, Hercules,
CA, USA).
Analysis of inflammatory markers in RVLM
Total protein extracted from RVLM was subject to quan-
titative analysis of TNF-α, IL-1β, IL-6, or prostaglandin
E2 (PGE2) by the sandwich ELISA (Bender MedSystems,
Burlingame, CA, USA) according to the procedures
described above. The concentration of each proinflam-
matory factor was expressed in picograms per milliliter
(pg/mL). All assays were performed in triplicate.
Western blot analysis
Total protein extracted from RVLM samples was subject
to Western blot analysis according to the procedures
described previously [20,22,24]. The primary antisera
used included goat polyclonal antiserum against p47phox
(1:5,000; Santa Cruz, CA, USA), rabbit polyclonal anti-
serum against Iba-1 (1:1,000; Wako, Tokyo, Japan), cata-
lase (1:4,000; Stressgen, Ann Arbor, MI, USA), copper/
zinc SOD (Cu/ZnSOD, 1:3,000; Stressgen), manganese
SOD (MnSOD, 1:6,000; Stressgen), extracellular SOD
(ecSOD, 1:5,000; Stressgen), goat polyclonal antiserum
against Kv4.3 (1:1,000; Santa Cruz), or mouse monoclo-
nal antiserum against glutathione peroxidase (GPx,
1:5,000; BD Biosciences), gp91phox (1:5,000; BD Bios-
ciences), endothelial NOS (eNOS, 1:5,000; BD Bios-
ciences), neuronal nitric oxide synthase (nNOS, 1:5,000;
BD Biosciences), inducible NOS (iNOS, 1:5,000; BD
Biosciences), COX-2 (1:1,000; Cayman, Ann Arbor, MI,
USA), or intercellular adhesion molecule-1 (ICAM-1)
(1:5,000; Abcam, Cambridge, MA, USA). Membranes
were washed with TBS-t buffer followed by the second-
ary antibodies (1:10,000; Jackson ImmunoResearch,
West Grove, PA, USA). This was followed by incubation
with horseradish peroxidase-conjugated goat anti-rabbit
IgG or goat anti-mouse IgG (Jackson ImmunoReserach).
Specific antibody-antigen complex was detected using an
enhanced chemiluminescence Western blot detection
system (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ, USA). The amount of detected protein was quantified
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by the Photo-Print Plus software (ETS Vilber-Lourmat,
Marne-la-Vallée, France), and was expressed as the ratio
to β-actin protein.
Measurement of superoxide anion
To measure the tissue level of O2•
-, the extracted proteins
(20 μg/test) from RVLM were incubated with the
oxidation-sensitive fluorescent probe dihydroethidium
(DHE, 1 μM; Invitrogen, Carlsbad, CA, USA). After
15 min of incubation under protection from light, the
suspension was subject to fluorescence analysis (Fluor-
Star; Biodirect, Inc., Taunton, MA, USA). All measure-
ments were performed in triplicate. For in situ
identification of O2•
- in RVLM, rats were killed with an
overdose of pentobarbital sodium (100 mg/kg, i.p.) and
perfused intracardially with warm saline. The brain stem
was rapidly removed, mounted in OCT compound
(Leica Microsystems, Nussloch, Germany), and frozen at
-20°C. A series of coronal sections (at 35 μm) through
the RVLM (0.5 to 1.5 mm rostral to the obex) were cut
using a cryostat (Leica, Houston, TX, USA). These sec-
tions were incubated for 30 min in the dark with DHE
(1 μM). After washing with phosphate buffered saline
(PBS), DHE fluorescence was visualized by fluorescence
microscopy (Olympus Optical, Tokyo, Japan) using an
excitation wavelength of 543 nm and a rhodamine emis-
sion filter [20,25].
Immunohistochemistry and immunofluorescence
Animals were perfused transcardially with 4% parafor-
maldehyde in 0.1 M PBS (pH 7.4) under deep pento-
barbital anesthesia (100 mg/kg, i.p.), and the brain
stem was removed and post-fixed overnight in the
same fixative, followed by 30% sucrose solution for at
least 3 days. Coronal sections of the rostral medulla
oblongata at 35 μm were cut using a cryostat (Leica).
After pre-absorption in gelatin (0.375%), normal horse
serum (3%), and triton-X 100 (0.2%) in PBS, the sec-
tions were incubated with a rabbit polyclonal antibody
against Iba-1 (1:1,000; Wako), at room temperature
overnight and then rinsed in PBS. After incubation in
biotinylated horse anti-rabbit IgG (1:200; Jackson
ImmunoResearch, the sections were rinsed in PBS and
incubated with AB complexes (Vectastain ABC elite
kit, Vector Laboratories, Burlingame, CA, USA). This
was followed by washing the sections in PBS and incu-
bated with a 3,30-diaminobenzidine substrate kit (Vector
Laboratories). Sections were counter stained with 1%
Neural Red, and observed under a light microscope
(Olympus) [26].
For immunofluorescence experiments, a mouse mono-
clonal antiserum against ICAM-1 (1:1,000, Biovision)
and a rabbit polyclonal antiserum against a blood glyco-
protein Von Willebrand factor (vWF; 1:1,000, Abcam)
were incubated at room temperature overnight. After in-
cubation in Alex 568 conjugated anti-mouse IgG (1:200;
Invitrogene) and Alex 488 conjugated anti-rabbit IgG
(1:200; Jackson Invitrogene), the sections were rinsed in
distilled water. Sections were mounted and observed
under a laser confocal microscope (FluoView FV10i,
Olympus) [20,25].
Quantitative evaluation of Evans blue extravasation
Blood-brain barrier disruption was assessed quantita-
tively by measuring Evans blue (EB; Sigma-Aldrich, St
Louis, MO, USA) extravasation [27]. Briefly, rats were
injected intravenously with 0.1 mL 2% EB, and the dye
was allowed to circulate for 60 min. The animals were
perfused transcardially with 0.9% PBS to remove intra-
vascular EB dye. Tissue sample from RVLM was
weighed and homogenized in 500 μL 0.1 M PBS and 500
μL of pure trichloroacetic acid (Sigma-Aldrich). Samples
were incubated at 4°C for at least 1 h and centrifuged at
10,000 g for 30 min. The resultant supernatants were
measured for absorbance of EB at 610 nm using a spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA,
USA). All measurements were performed in triplicate.
Intracisternal infusion of test agents
Intracisternal (IC) infusion of test agents was carried out
according to the previously described procedures
[20,25]. In brief, after the dura mater between the for-
amen magnum and C1 lamina was perforated with a 22-
gauge steel needle, a PE-10 catheter (Clay Adams,
Sparks, MD, USA) was advanced for 5 mm into the cis-
terna magna. The catheter was sealed to the dura with
tissue glue and the incision was closed with layered
sutures. The outer end of the catheter was connected to
an osmotic minipump (Alzet 1002), which was placed
under the skin in the neck region [20,25]. IC infusion of
a cyclooxygenases-2 (COX-2) inhibitor [28], NS398; an
inhibitor of microglial activation [29], minocycline; a
cytokine synthesis inhibitor [30], pentoxifylline (PTX) or
a superoxide dismutase (SOD) mimetic [31], tempol was
carried out for 14 days. Control infusion of artificial CSF
(aCSF) served as the volume and vehicle control.
Microinjection of test agents into RVLM
Microinjection bilaterally of test agents into RVLM was
carried out according to procedures described previously
[18-20,24,25] in animals maintained under propofol
anesthesia (20 mg/kg/h, Zeneca, Macclesfield, UK).
Microinjection was carried out with a glass micropipette
(external tip diameter 50 to 80 μm) connected to a
0.5-μL Hamilton microsyringe (Reno, NV, USA). The
stereotaxic coordinates for RVLM were: 4.5 to 5.0 mm
posterior to lambda, 1.8 to 2.1 mm lateral to midline,
and 8.0 to 8.5 mm below dorsal surface of cerebellum.
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These coordinates were selected to cover the extent of
ventrolateral medulla in which functionally identified
sympathetic premotor neurons reside. As a routine, a
total volume of 50 nL was delivered over 2 to 3 min to
allow for complete diffusion of the test agents. Accuracy
of the microinjection was confirmed by histological
examination of the injection sites. The chemicals used
included a superoxide dismutase mimetic, tempol.
Microinjection of aCSF served as volume and vehicle
control.
Statistical analysis
Data are expressed as means ± SEM. The statistical soft-
ware SigmaStat (SPSS, Chicago, IL, USA) was used for
data analysis. One-way or two-way analysis of variance
with repeated measures was used, as appropriate, to as-
sess group means, to be followed by the Scheffé
multiple-range test for post hoc assessment of individual
means. A P value <0.05 was considered statistically
significant.
Results
Chronic systemic infusion of LPS induces hypertension
Compared to saline, infusion of LPS (1.2 mg/kg/day)
into the peritoneal cavity by an osmotic minipump
induced an increase in mean SAP (MSAP) that became
significant on day 3 and lasted for at least 14 days post-
infusion (Figure 1A). Of note was the LPS-induced
hypertension was significantly inhibited by concurrent
IC infusion of a COX-2 inhibitor, NS398 (1.5 nmol/μL/h).
However, IP infusion of LPS, alone or with additional
IC infusion of NS398, had no significant effect on HR
(Figure 1B). Since the LPS-induced hypertension was
sustained at a comparable level, subsequent biochemical
analyses were carried out at day 7 and/or day 14 to re-
duce the number of animals used. On day 14 after IP in-
fusion of the endotoxin, there is no significant change in
body weight (266±3 vs. 260±6 g, P >0.05, n=16), body
temperature (36±1 vs. 37±2°C, P >0.05, n=16), daily food
(22±5 vs. 23±5 g/day, P >0.05, n=16), or water (47±5 vs.
50±7 mL/day, P >0.05, n=16) intake between the saline-
and LPS-treated animals.
Chronic systemic infusion of LPS induces inflammatory
response
Hypertension induced by IP infusion of LPS was accom-
panied by an increase in plasma levels of CRP, TNFα,
and IL-1β, detected on day 7 or 14 after infusion of the
endotoxin (Figure 1C to 1E). However, the LPS-induced
systemic inflammatory response was not significantly
affected by infusion of NS398 (1.5 nmol/μL/h) into the
cisterna magna.
Chronic systemic LPS infusion upregulates COX-2-
dependent expression of pro-inflammatory cytokines in
RVLM
IP infusion of LPS for 14 days also promoted a signifi-
cant increase in tissue levels of TNF-α, IL-1β, or IL-6 in
RVLM (Figure 2) that became significant on day 3 and
lasted for at least 14 days. Whereas concurrent IC infu-
sion of NS398 (1.5 nmol/μL/h) significantly blunted the
upregulation of proinflammatory cytokines in RVLM, IC
infusion of a SOD mimetic, tempol (1 μmol/μL/h)
exerted no discernible effect on the elevated TNF-α,
IL-1β, or IL-6 when determined on day 7 after the in-
duction of systemic inflammation. Basal levels of pro-
inflammatory cytokines in RVLM were comparable
among the experimental groups (data not shown).
Microglial activation and COX-2 upregulation in RVLM
following chronic systemic LPS infusion
Compared to saline infusion, the expression of Iba-1
protein, an experimental index for activated microglia
[32], and distribution of Iba-1 immunoreactivity in
RVLM were markedly increased when measured on day
3 or 7 (data not shown) following IP infusion of LPS;
and was antagonized by IC infusion of minocycline
(9 nmol/μL/h), an inhibitor of microglial activation
(Figure 3A and B). Systemic LPS infusion also increased
COX-2 expression and activity, alongside production of
PGE2, which were blunted by concurrent IC infusion of
minocycline (Figure 3C to E). Treatment with minocy-
cline also significantly antagonized the increase in tissue
levels of TNF-α (1.69±0.09 vs. 0.74±0.04 pg/μg protein,
P<0.05, n=12) or IL-1β (16.77±1.67 vs. 12.13±1.10 pg/μg
protein, P<0.05, n=12) in RVLM induced by systemic
LPS infusion. The same agent when infused into the
peritoneal cavity had no significant effect on the
increased expression of TNF-α(1.69±0.09vs.1.77±0.07pg/
μg protein, P>0.05, n=6) or IL-1β (16.77±1.67 vs. 16.40
±1.74 pg/μg protein, P>0.05, n=12) in RVLM measured
on day 3 following systemic LPS infusion.
Endothelial dysfunction in RVLM following chronic
systemic LPS infusion
Systemic LPS infusion for 14 days significantly reduced
endothelial nitric oxide synthase (eNOS) (Figure 4A) but
augmented inducible NOS (iNOS) (Figure 4B) protein
expression in RVLM, determined on day 7 or 14 (data
not shown) postinfusion. IC infusion of NS398 (1.5 nmol/
μL/h) antagonized the elevated iNOS expression and
reverted eNOS expression from a reduction to an aug-
mentation. However, no apparent change in neuronal
NOS (nNOS) expression in RVLM was detected in
rats that received peripheral LPS infusion, which was
similarly unaffected by NS398 (Figure 4C). Systemic
infusion of LPS also increased ICAM-1 expression in
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RVLM, which was not antagonized by IC infusion
NS398 (Figure 4D). Viewed under confocal microscopy,
ICAM-1-immunoreactivity was found to co-localize with
vWF-immunoreactivity in blood vessels (Figure 4E). LPS,
however, did not affect the integrity of the blood–brain
barrier, as determined by a maintained extravasation of
Evans Blue dye in RVLM tissue (saline: 10.6±3.5 vs. LPS:
13.8±4.3 μg/g tissue, P >0.05, n=8).
Microglial activation and COX-2 upregulation in RVLM
underpin hypertension induced by chronic systemic LPS
infusion
The pressor response detected on day 14 after IP infu-
sion of LPS was significantly attenuated by IC infusion
of minocycline (9 nmol/μL/h) (145±5 vs. 111±5 mmHg,
P <0.05, n=12) or a cytokine synthesis inhibitor, PTX
(30 nmol/μL/h) (145±5 vs. 115±6 mmHg, P <0.05,
Figure 1 Infusion of LPS into the peritoneal cavity elevates blood pressure and plasma level of pro-inflammatory cytokines.
Time-course changes in mean SAP (MSAP) (A), HR (B), or plasma level of CRP (C), TNF-α (D), and IL-1β (E), measured on days 7 or 14 after
intraperitoneal infusion of saline or LPS (1.2 mg/kg/day) via an osmotic minipump for 14 days, alone or with additional intracisternal infusion of
NS398 (1.5 nmol/μL/h). Values are mean± SEM (n=8 to 10 animals in each experimental group). *P <0.05 vs. saline-treatment group at
corresponding time-intervals or sham-control group; #P <0.05 vs. LPS-treatment group at corresponding time-intervals in the post hoc Scheffé
multiple-range test. Arrow indicates the time point during which the osmotic minipump was implanted into the peritoneal cavity.
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n=12). Infusion into the peritoneal cavity of the same
test agents, on the other hand, was ineffective to affect
LPS-induced hypertension measured on day 14 postinfu-
sion (minocylcine: 127±3.1 vs. 132±4.0 mmHg, P >0.05,
n=8; PTX: 127±3.1 vs. 123±3.8 mmHg, P >0.05, n=8).
Increase in superoxide production in RVLM following
chronic systemic LPS infusion
The manifestation of DHE-positive cells and tissue level of
O2•
- in RVLM, measured on day 7 after IP infusion of LPS
(1.2 mg/kg/day), were significantly increased (Figure 5).
This induced increase in O2•
- production in RVLM was
abolished by IC infusion of NS398 (1.5 nmol/μL/h)
(Figures 5A and B), minocycline (9 nmol/μL/h), PTX
(30 nmol/μL/h) (Figure 5B), or tempol (1 μmol/μL/h)
(Figure 5B).
Upregulation of the NADPH oxidase subunits and
antioxidants expression in RVLM following chronic
systemic LPS infusion
IP infusion of LPS for 14 days resulted in a significant
increase in the expression of gp91phox and p47phox subu-
nits of NADPH oxidase, which were detected on day 5
(data not shown) and peaked on day 7 (Figure 6A and B)
postinfusion. This upregulation was antagonized by
IC infusion of NS398 (1.5 nmol/μL/h) or minocycline
(9 nmol/μL/h). Systemic infusion of LPS also upregu-
lated the expression of Cu/ZnSOD (Figure 6C), catalase
(Figure 6F), or GPx (Figure 6G) in RVLM, but not
MnSOD (Figure 6D) or ecSOD (Figure 6E), detected on
day 7 and 14 (data not shown) postinfusion. The aug-
mented expression of the antioxidant was blunted by
IC infusion of NS398 (1.5 nmol/μL/h) or minocycline
(9 nmol/μL/h).
Oxidative stress in RVLM underpins hypertension induced
by chronic systemic infusion of LPS
IC infusion of tempol (1 μmol/μL/h) significantly atten-
uated the pressor response to IP infusion of LPS
(1.2 mg/kg/day) (Figure 7A). Comparable results were
observed acutely for at least 120 min following micro-
injection of tempol (100 pmol) into the bilateral RVLM
(Figure 7B), but not intravenous administration (125±
2.1 vs. 130±2.8 mmHg, P >0.05, n=8) at the same dose.
IC infusion of tempol, on the other hand, had no appre-
ciable effect on the increase in plasma CRP following
LPS infusion (Figure 7C).
Redox-sensitive downregulation of Kv4.3 potassium
channel in RVLM following chronic systemic infusion of
LPS
IP infusion of LPS (1.2 mg/kg/day) significantly downre-
gulated the protein expression of the voltage-gated po-
tassium channel, Kv4.3, in RVLM (Figure 8A). This
induced downregulation of Kv4.3 was attenuated in animals
that received IC infusion of minocycline (9 nmol/μL/h),
NS398 (1.5 nmol/μL/h), PTX (30 nmol/μL/h), or tempol
(1 μmol/μL/h).
Neuroinflammation- and oxidative stress-associated
increase in neurogenic sympathetic vasomotor activity
following chronic systemic infusion of LPS
IP infusion of LPS (1.2 mg/kg/day) significantly increased
the power density of the LF component of SAP signal
Figure 2 Intraperitoneal infusion of LPS also elevates tissue
level of pro-inflammatory cytokines in RVLM. Left panels: Time-
course changes in tissue level of TNF-α, IL-1β, or IL-6 in RVLM after
intraperitoneal infusion of saline or LPS (1.2 mg/kg/day), alone or
with additional intracisternal infusion of NS398 (1.5 nmol/μL/h).
Right panels: Tissue level of the proinflammatory cytokines in RVLM
measured on day 7 after intraperitoneal LPS infusion, with additional
intracisternal infusion of tempol (1 μmol/μL/h) or aCSF. Values are
mean± SEM (n=8 to 10 animals in each experimental group).
*P <0.05 vs. corresponding saline-treatment group; #P <0.05 vs.
corresponding LPS-treatment group in the post hoc Scheffé
multiple-range test.
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(Figure 8B). This induced increase in our experimental
index of neurogenic sympathetic vasomotor activity [22]
was attenuated in animals that received IC infusion of
minocycline (9 nmol/μL/h), NS398 (1.5 nmol/μL/h), PTX
(30 nmol/μL/h), or tempol (1 μmol/μL/h).
Discussion
Chronic systemic inflammation contributes to the patho-
genesis of hypertension. The findings of the present
study suggest that neuroinflammation and oxidative
stress in RVLM play an active role in this process. Our
results showed that systemic inflammation causes endo-
thelial dysfunction and activates microglia in RVLM to
induce COX-2-dependent neuroinflammation that leads
to an increase in O2•
- production, contributing to an in-
crease in sympathetic neurogenic vasomotor tone and
neurogenic hypertension possibly via downregulation of
Kv4.3 potassium channel expression.
IP infusion of gram-negative bacterial endotoxin LPS
is a well-characterized rodent model of systemic inflam-
mation. In contrast to high-dose endotoxin that induces
a robust yet transient inflammatory response, low-dose
endotoxin causes low-grade yet persistent inflammatory
responses from the host, as reflected in the mildly sus-
tained levels of inflammatory mediators [33,34]. Indeed,
IP infusion of Escherichia coli LPS at the dose used in
Figure 3 Systemic inflammation activates microglia and enhances COX-2 activity in RVLM. Gels (inset) and densitometric analysis of results
from Western blot showing changes in expression of Iba-1 (A) or COX-2 (C), or representative photomicrographs showing immunoreactivity to
Iba-1 (black color) (B), COX-2 activity (D), or tissue level of PGE2 (E) in RVLM, examined on day 7 after intraperitoneal infusion of saline or LPS
(1.2 mg/kg/day), alone or with additional intracisternal infusion of minocycline (9 nmol/μL/). Values are mean± SEM (n=8 to 10 animals in each
experimental group). *P <0.05 vs. saline-treatment group; #P <0.05 vs. LPS-treatment group in the post hoc Scheffé multiple-range test. Scale bar
in (A): 25 μm.
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the present study resulted in a significant increase in
plasma level of pro-inflammatory cytokine and a moder-
ate increase in plasma level of CRP that is comparable
to low-grade systemic inflammation elicited by peri-
odontal bacteria [35] or hyperlipidic diet [36]. CRP is a
marker for systemic inflammation [37] and is a risk pre-
dictor for symptomatic peripheral arterial diseases [38].
In an earlier clinical study [38], development of vascular
diseases and hypertension is more prevalent in partici-
pants with an approximately 35% increase in plasma
CRP. With a comparable increase in plasma CRP of 27
±5% on IP infusion of LPS, our animal model should
suitably predict augmented risks of the rats in developing
hypertension. Recent clinical studies [39-41] further indi-
cate that low-grade systemic inflammation is associated
with a variety of human chronic cardiovascular diseases,
including atherosclerosis, diabetes, heart failure, and
hypertension.
A major finding in the present study is that the LPS-
induced systemic inflammation is associated with neu-
roinflammation in RVLM. In particular, the temporal
profile of the augmented levels of TNF-α, IL-1β, IL-6, or
iNOS in RVLM after IP infusion of LPS paralleled that
of the elevated plasma pro-inflammatory cytokines and
CRP levels. Since most of the blood-borne inflammatory
cytokines have restricted access to the brain due to poor
passage through the blood-brain barrier [42] and our
present finding of an intact blood-brain barrier following
systemic LPS infusion, it is conceivable that the observed
neuroinflammation in RVLM may not result from direct
Figure 4 Intraperitoneal infusion of LPS induces endothelial dysfunction in RVLM. Representative gels (inset) and densitometric analysis of
results from Western blot showing changes in expression of eNOS (A), iNOS (B), nNOS (C), or ICAM-1 (D), as well as photomicrographs showing
distribution of vWF- (red fluorescence) and ICAM-1-immunoreactivity (green fluorescence) in RVLM, examined on day 7 after intraperitoneal
infusion of saline or LPS (1.2 mg/kg/day), alone or with additional intracisternal infusion of NS398 (1.5 nmol/μL/h). Values are mean± SEM (n=8 to
10 animals in each experimental group). *P <0.05 vs. saline-treatment group; #P <0.05 vs. LPS-treatment group in the post hoc Scheffé multiple-
range test. Note that colocalization of vWF- and ICAM-1-immunoreactivity is shown in yellow color in (D). Scale bar in (D): 10 μm.
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entry of blood-borne inflammatory cytokines to this neural
substrate. Systemic administration of LPS has been demon-
strated to induce an innate immune response in brain
[14,43]. Thus, it is of interest to find in the present study
that microglia was activated in RVLM and the increase in
protein expression and enzyme activity of COX-2 was pre-
vented by an inhibition of microglial activation. Further-
more, inhibition of COX-2 ameliorated the augmented
expression of the proinflammatory cytokines and iNOS in
RVLM. These results therefore complement previous
reports [8,44], and suggest that microglial activation and
COX-2-dependent mechanism mediate the transfer of sys-
temic inflammation to neuroinflammation in RVLM. The
ineffectiveness of IC infusion of NS398 to inhibit periph-
eral inflammation deems unlikely the antagonism of neu-
roinflammation in RVLM by the COX-2 inhibitor is
secondary to leakage to systemic circulation. PGE2, the
eicosanoid product of COX, was reported to mediate the
initiation and development of inflammation after entering
the brain [15,45]. A reversal by minocycline and NS398 on
PGE2 production in RVLM implies the involvement of
COX-PGE2 signaling in mediating neuroinflammation in
RVLM following systemic inflammation. It is noteworthy
that the expression of proinflammatory cytokines detected
in RVLM in this model of LPS-induced neurogenic hyper-
tension is comparable to that found in the brain of other
animal models of hypertension with neurogenic compo-
nents, including chronic infusion of angiotensin II [7,14,46]
and spontaneously hypertensive rats [5,10,12]. Together,
they highlight the importance of neuroinflammation in the
manifestation of neurogenic hypertension in a variety of
animal model of hypertension.
The endothelium effectively maintains an anti-inflammatory
environment under normal conditions [47]. In addition,
a loss of endothelial integrity and an increase in expression
of adhesion molecules are important attributes to tissue
damage during inflammation [48]. We showed in the
present study that endothelial dysfunction, characterized
by a downregulation of eNOS and an upregulation of
ICAM-1 in blood vessels occurred in RVLM following
chronic systemic inflammation. The observation that
IC infusion of a COX-2 inhibitor exerted minimal effect
on ICAM-1 upregulation in RVLM suggests that COX-2
activation is downstream to the loss of endothelial in-
tegrity in RVLM. That IC infusion of NS398 reverted
eNOS expression from a reduction to an augmentation
further suggested the presence of a rebound compensatory
mechanism.
We reported previously [24,49] that generation of O2•
-
in RVLM because of an upregulation of gp91phox or
p47phox subunit of NADPH oxidase underlies neuro-
genic hypertension. The present study further showed
that this oxidative stress elicited by systemic inflamma-
tion is downstream to microglial activation via a COX-2-
dependent mechanism. These results are parallel to a re-
cent report [50] on the production of O2•
- in the PVN to
neuroinflammation induced by intracerebroventricular
administration of LPS. Mechanisms involved in activa-
tion of NADPH oxidase in RVLM under neuroinflam-
mation is not immediately clear. In this regard, the
enzyme activity of Rac, a member of the Rho family
small GTPases that plays a crucial role in activation of
Figure 5 Intraperitoneal infusion of LPS induces
neuroinflammation-associated oxidative stress in RVLM.
Representative photomicrographs showing the distribution of
dihydroethidium (red fluorescence) (A), or changes in tissue level of
superoxide (B) in RVLM examined on day 7 after intraperitoneal
infusion of saline or LPS (1.2 mg/kg/day), alone or with additional
intracisternal infusion of minocycline (9 nmol/μL/h), pentoxifylline
(PTX, 30 nmol/μL/h), NS398 (1.5 nmol/μL/h), or tempol (1 μmol/μL/h).
Values are mean±SEM (n=8 to 10 animals in each experimental group).
*P <0.05 vs. saline-treatment group; #P <0.05 vs. LPS-treatment group in
the post hoc Scheffé multiple-range test. A schematic drawing of rostral
medulla oblongata is included in (A) to illustrate the location of RVLM
from where the photomicrographs were taken. NA, nucleus ambiguous;
NTS, nucleus tractus solitarii; V, nucleus spinalis trigemini. Scale bar in (A):
100 μm.
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NADPH oxidases [51], was reported to be activated by
microglia-specific protein Iba-1 under inflammation
condition [52]. Based on the temporal expression pro-
files, our results showed that upregulation of gp91phox or
p47phox subunit of NADPH oxidase after systemic in-
flammation precedes that of the increases in Cu/ZnSOD,
catalase, or GPx in RVLM. The antagonism by IC infu-
sion of NS398 or tempol on upregulation of the antioxi-
dants may represent yet another cellular compensatory
response to cope with oxidative stress induced by neu-
roinflammation in RVLM. Our findings of a sustained
increase in O2•
- despite upregulation of antioxidants
further suggest that the production of O2•
- in RVLM
may exceed its degradation under neuroinflammation.
Alternatively, it may result from inhibition of enzyme
activities of the antioxidants by neuroinflammation. A
lack of change in MnSOD expression in RVLM may
imply a differential involvement of cytosolic versus
mitochondrial antioxidant in this compensatory re-
sponse under neuroinflammation.
Results from our physiological evaluations provided the
crucial documentation that oxidative stress induced by
COX-2-dependent neuroinflammation in RVLM under-
pins the hypertension elicited by chronic systemic inflam-
mation. We found that the progression of hypertension
coincided temporally with the appearance of neuroinflam-
mation and oxidative stress in RVLM after IP infusion of
LPS, which was similarly antagonized by IC, but not
systemic infusion of minocycline, NS398, PTX or tempol.
The suppression of LPS-induced increase in sympathetic
neurogenic vasomotor activity by the same treatments
further indicates that the oxidative stress-associated
neurogenic hypertension in response to neuroinflamma-
tion in RVLM is mediated via an increase in sympathetic
outflow to the blood vessels. Since microinjection of tem-
pol into RVLM only partially blunted the LPS-induced
hypertension, the contribution by oxidative stress in other
brain regions cannot be ruled out. In this regard, oxida-
tive stress in PVN [50,53] and nucleus tractus solitarii
[12,54] contributes to the pathogenesis of neurogenic
Figure 6 Intraperitoneal infusion of LPS upregulates NADPH oxidase subunits and antioxidants in RVLM. Representative gels (inset) and
densitometric analysis of results from Western blot showing changes in expression of gp91phox (A), p47phox (B), Cu/ZnSOD (C), MnSOD (D),
ecSOD (E), catalase (F), or glutathione peroxide (GPx) (G) in RVLM, determined on day 7 after intraperitoneal infusion of saline or LPS (1.2 mg/kg/
day), alone or with additional intracisternal infusion of NS398 (1.5 nmol/μL/h) or minocycline (9 nmol/μL/h). Values are mean± SEM (n=8 to 10
animals in each experimental group). *P <0.05 vs. saline-treatment group; #P <0.05 vs. LPS-treatment group in the post hoc Scheffé multiple-range
test.
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hypertension, and neuroinflammation occurs in both
brain regions [4,8,12,50] in response to systemic inflam-
mation. In addition, a recent study [55] reported that
COX-1-derived PGE2 signaling in the subfornical organ
is required for ROS-mediated neurogenic hypertension
induced by systemic infusion of angiotensin II.
The A-type voltage-gated potassium (Kv) channels
play pivotal roles in regulating the intrinsic excitability
and the firing properties of neurons. The functional di-
versity of neuronal Kv currents is generated, in part,
through the expression of multiple Kv channel pore-
forming (α) subunits [56]. We found in the present study
that neuroinflammation in RVLM following systemic
LPS infusion was associated with a redox-sensitive re-
duction in the expression of Kv4.3 channel protein
because of microglial activation and the presence of
COX-2 and cytokine. Kv4.3 contributes to the transient
outward potassium current; and its activation leads to
reduction in neuronal excitability by increasing the
Figure 7 Oxidative stress in RVLM underpins hypertension
induced by intraperitoneal infusion of LPS. Changes in MSAP
(A,B) or plasma level of CRP (C) determined on day 7 after
intraperitoneal infusion of saline or LPS (1.2 mg/kg/day), alone or
with additional intracisternal infusion of aCSF or tempol (1μmol/μL/h)
(A,C), or microinjection bilaterally into RVLM of tempol (100 pmol) (B).
Values are mean±SEM (n=8 to 10 animals in each experimental group).
*P <0.05 vs. saline-treatment or sham-control group; #P <0.05 vs. LPS-
treatment group in the post hoc Scheffé multiple-range test.
Figure 8 Intraperitoneal infusion of LPS downregulates Kv4.3
potassium channel in RVLM and increase the sympathetic
neurogenic vasomotor activity. Representative gels (inset) and
densitometric analysis of results from Western blot showing changes
in expression of Kv4.3 channel protein in RVLM (A) or changes in
the power density of the low frequency component of SAP
spectrum (B), measured on day 7 after intraperitoneal infusion of
saline or LPS (1.2 mg/kg/day), alone or with additional intracisternal
infusion of minocycline (9 nmol/μL/h), NS398 (1.5 nmol/μL/h), PTX
(30 nmol/μL/h), or tempol (1 μmol/μL/h). Values are mean± SEM
(n=8 to 10 animals in each experimental group). *P <0.05 vs. saline-
treatment group; #P <0.05 vs. LPS-treatment group in the post hoc
Scheffé multiple-range test.
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duration of action potential [57]. By reducing Kv4.3
channel protein expression, it is thus reasonable to
speculate that neuroinflammation in RVLM promotes
hypertension via sympathoexcitation that may result
from a redox-sensitive increase in neuronal excitability.
In RVLM, redox-sensitive downregulation of Kv4.3 po-
tassium channel was reported [58] to mediate sym-
pathoexcitation in heart failure. We noted that apart
from Kv4.3, Kv1.4 and Kv4.2 are also sensitive to tissue
inflammation [59]. The contribution of these pore-
forming subunits of potassium channel in RVLM in
redox-sensitive sympathoexcitation under neuroinflam-
mation, however, awaits further delineation. It is also
noteworthy that whereas nNOS-derived NO in RVLM
mediates pressor response via activation of sympathetic
vasomotor activity [60], the minimal alteration in nNOS
expression during chronic systemic inflammation sug-
gests that this signaling pathway plays a minor role in
the pathogenesis of neurogenic hypertension during
chronic systemic inflammation.
Hypertension alone activates circulating T-cells to de-
velop vascular inflammation [7]. Moreover, LPS pro-
duces a robust inflammatory reaction in brain, which is
significantly diminished when the pressor responses is
normalized with angiotensin II receptor antagonist [14].
It thus is possible that neuroinflammation in RVLM may
be secondary to systemic hypertension induced by IP in-
fusion of the endotoxin. Our preliminary results indi-
cated that this possibility is not operable. Oral intake for
7 days of amlodipine, a calcium channel inhibitor that
normalizes hypertension with minimal central actions
[61], promoted a decrease in blood pressure with min-
imal effect on the increases in pro-inflammatory cyto-
kine expression or O2•
- production in RVLM after
chronic systemic inflammation. The possibility that
blood-borne, instead of cytokines produced in RVLM
underlies the observed hypertension after IP infusion of
LPS is also deemed minimal. IC infusion of NS398, at a
dose that reduced pressor responses and inhibited pro-
inflammatory cytokines expression in RVLM exerted
minimal effect on the increase in plasma TNF-α, IL-1β,
or CRP level. Furthermore, IP infusion of same dose of
PTX or NS398 was also ineffective against the induced
hypertension following systemic inflammation.
Conclusion
Our results support the novel notion that chronic
systemic inflammation causes endothelial dysfunction,
activates microglia and induces COX-2-dependent neu-
roinflammation, followed by oxidative stress in RVLM
that leads to the development of neurogenic hyperten-
sion possibly via downregulation of the voltage-gated
Kv4.3 channel. A feed-forward mechanism for the devel-
opment of hypertension under chronic inflammation
was proposed [7]. According to this proposal, a modest
degree of elevation in blood pressure promotes inflam-
mation that further raises blood pressure, leading to se-
vere hypertension. Our results added a new dimension
to this proposal by demonstrating that the pathogenesis
of hypertension during chronic systemic inflammation
can take origin from brain via neuroinflammation-
associated oxidative stress in RVLM. We further
extended the previous studies [4,8,12,62] to reveal that
ROS, in particular O2•
-, may serve as the crucial link be-
tween systemic inflammation, neuroinflammation, and
neurogenic hypertension.
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